iProtics

iProtics is a pioneering biotechnology research company focused on transforming the treatment of cancer and auto-immune disorders. With a profound understanding of proteasomes, vital protein-regulating complexes, iProtics is dedicated to developing selective immunoproteasome inhibitors. These innovative inhibitors are designed to precisely target disease-causing cells, ensuring the preservation of healthy tissues. iProtics aims to offer a groundbreaking shift from current clinical drugs that often affect both cancerous and somatic cells indiscriminately.

The primary address of iProtics is in Leiden, NL. Built upon the significant discoveries of the Overkleeft group at Leiden University, iProtics leverages a skilled team with expertise in design, synthesis, drug development, and business strategies. The company's innovative approach promises to enhance treatment efficacy and reduce adverse effects, ultimately improving patient outcomes in oncology and autoimmune disease therapies.

iProtics is poised to make significant contributions to the biotechnology landscape. The company’s commitment to precision and selectivity in drug development positions iProtics as a leader in the next generation of targeted therapeutics. We invite the manager of iProtics to create a customized and exclusive company showcase and product listing on our platform to further amplify their reach and impact.